Please assess the completion status of the following clinical trial:

Trial Title: Aplidin - Dexamethasone in Relapsed/Refractory Myeloma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 18 years.~* Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) ≤ 2~* Life expectancy ≥ 3 months.~* Patients previously diagnosed with multiple myeloma~* Patients must have relapsed or relapsed and refractory multiple myeloma (MM) after at least three but not more than six prior therapeutic regimens for MM, including induction therapy and stem cell transplant in candidate patients, which will be considered as only one regimen.~* Patients must have received previous bortezomib-containing and lenalidomide-containing regimens (or thalidomide where lenalidomide is not available)~* Women must have a negative serum pregnancy test~* Voluntarily signed and dated written informed consent~Exclusion Criteria:~* Concomitant diseases/conditions~* Women who are pregnant or breast feeding.~* Concomitant medications that include corticosteroids, chemotherapy, or other therapy that is or may be active against MM~* Known hypersensitivity to any involved study drug or any of its formulation components

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Plitidepsin+Dexamethasone (Type: EXPERIMENTAL): plitidepsin + dexamethasone combination
- Dexamethasone (Type: ACTIVE_COMPARATOR): dexamethasone single agent

Based on this trial design, predict the completion outcome and termination type (if applicable).